1. Scrip
  2. >>Business

Novo Nordisk Puts $2.3bn Into Manufacturing, But Won’t Aid Wegovy Supply Woes

 
• By Joseph Haas

Company says its new API production facility in Denmark will come online in 2029 and help meet demand for pipeline products in serious chronic diseases. Novo is currently contending with supply crunches for its semaglutide products.

Manufacturing
Novo Nordisk is adding to its API manufacturing capacity in Denmark • Source: Shutterstock

Novo Nordisk A/S, which has been struggling over the past year to meet US demand for its semaglutide products, announced on 12 June it is committing DKK15.9bn (nearly $2.3bn) to expand its manufacturing capacity for active pharmaceutical ingredients (APIs) in Denmark, but this initiative does not appear to offer any relief for supply issues related to the pharma’s current commercial portfolio.

The metabolic disease specialist said it will begin work this year on new API facilities in its home country, but projected that the new facility will not come online until 2029. The 65,000-square-meter facility in Hillerød, Denmark, will expand Novo Nordisk’s API production capacity for “the future portfolio in serious chronic diseases,” the company said

More from Manufacturing

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.